Clinical Trial Update: Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Ningetinib in advanced non-small cell lung cancer with MET exon 14 skipping mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ningetinib (Ningetinib)

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Advanced NSCLC | Phase 2 | Status: UNKNOWN